VRXA Latest Press Releases

-- October 13, 2026 --

VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC-ADC Technology at World ADC Congress Globe Newswire 7:00 AM

-- October 7, 2026 --

VERAXA Biotech Provides Overview on Implementation of FDA-Aligned Human-Relevant Models into R&D Strategy Globe Newswire 7:00 AM

-- September 4, 2026 --

VERAXA Biotech Appoints Raju Willener as Chief Financial Officer Globe Newswire 7:00 AM

-- August 24, 2026 --

VERAXA Biotech and Secarna Pharmaceuticals Achieve Research Milestone in Antibody Oligonucleotide Conjugate (AOC) Alliance Globe Newswire 7:00 AM

-- July 29, 2026 --

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates Globe Newswire 7:00 AM

-- July 27, 2026 --

VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb Globe Newswire 7:00 AM

-- July 24, 2026 --

VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth Globe Newswire 4:05 PM

-- July 23, 2026 --

VERAXA Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance BiTAC Technology Platforms and Portfolio Globe Newswire 7:00 AM

-- July 20, 2026 --

VERAXA Biotech Announces Regulatory Progress with its BiTAC-TCE Development Plan Globe Newswire 7:00 AM

-- July 13, 2026 --

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC Pipeline Globe Newswire 7:00 AM

-- July 10, 2026 --

VERAXA Biotech AG Appoints Carl von Halem as Interim Chief Financial Officer and Successor to Torsten Brgermeister Globe Newswire 4:05 PM

-- July 6, 2026 --

VERAXA Biotech Provides Business Update and Further Details on Partnering Strategy and Development Timelines Globe Newswire 7:00 AM

-- July 2, 2026 --

VERAXA Biotech Initiates Cell Line Development with ATUM to Advance its Lead BiTAC-TCE Program Globe Newswire 7:00 AM

-- June 24, 2026 --

VERAXA Biotech Expands R&D Hub in Heidelberg as Innovative BiTAC -TCE and ADC Programs Advance Towards Clinical Development Globe Newswire 7:00 AM

-- June 18, 2026 --

VERAXA Biotech Establishes in vitro Proof-of-Concept for Novel BiTAC-ADC Technology Platform and Launches Partnering Discussions at BIO International Convention 2026 Globe Newswire 7:00 AM

Market Data Delayed 15 Minutes